Evidence map›Paper›PMID 41438137›Full record

ArticleMolecular therapy. Oncology2025

Using the iCasp9 suicide strategy to control the growth and function of genome-edited B cells with redirected antigen specificity.

Jenny Léonard, Marine Cahen, Anne-Laure Tanguy, Laurent Deleurme, Natsuko Ueda, Ophélie Dézé, Grégory Noël, Maiwenn Pineau, Christophe Ferrand, Yannic Danger and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jenny LéonardINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Marine CahenINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Anne-Laure TanguyINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Laurent DeleurmeINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Natsuko UedaINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Ophélie DézéINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Grégory NoëlINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Maiwenn PineauINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Christophe FerrandINSERM UMR1098, EFS BFC, Université de Bourgogne Franche-Comté, 25000 Besançon, France.
Yannic DangerINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.
Michel CognéINSERM UMR1236, University of Rennes, Etablissement Français du sang, 35000 Rennes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cells could be effective immunotherapeutic "drug cells," but reports of genomic editing to redirect their specificity have not included safety strategies. To address the potential complications of cell therapy, there is a growing demand for integrated safety switches. This is particularly pertinent in the case of B cells, which are prone to malignant transformation. We evaluated in B cells the efficacy of inserting the inducible caspase-9 (iCasp9) suicide gene, together with either a reporter gene or a single-chain immunoglobulin cassette specific for a tumor antigen. We demonstrate that a single edit of the IgH locus enables the expression of both iCasp9 and the cassette hijacking antigen specificity, while preserving B cell functionality. In both primary and malignant lymphoma B cells, activation of iCasp9 using the drug AP1903 readily induced apoptosis of edited cells, both

Indexed as

adoptive immunotherapyB cellengineered B cellsgenome editingMT: Regular Issuesuicide gene

Identifiers

PMID41438137
PMCPMC12721158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.